Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Pharmacodynamic Study of MRX34, A Liposomal Microrna-34 Mimic, In Advanced Solid Tumours

Trial Profile

A Phase Ib Pharmacodynamic Study of MRX34, A Liposomal Microrna-34 Mimic, In Advanced Solid Tumours

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRX 34 (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as per Mirna Therapeutics media release.
    • 29 Mar 2016 According to a Mirna Therapeutics media release, this trial is expected to begin in late 2016.
    • 27 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top